ciclobendazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anthelminthics, tiabendazole derivatives 3120 31431-43-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cyclobendazole
  • ciclobendazole
  • Molecular weight: 259.27
  • Formula: C13H13N3O3
  • CLOGP: 2.06
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 84.08
  • ALOGS: -3.06
  • ROTB: 4

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.161 Moderate 0.70
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.052 Moderate 0.70
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 80.724 10^-6 cm/s Moderate 0.70
dh-clint Dog hepatocyte intrinsic clearance 20.606 uL/min/10^6 cells Moderate 0.70
dppb Dog plasma protein binding (% unbound) 25.700 % Moderate 0.70
fcs-ppb Fetal calf serum protein binding (% unbound) 45.640 % Moderate 0.70
herg hERG pIC50 3.944 pIC50 Moderate 0.70
hh-clint Human hepatocyte intrinsic clearance 4.477 uL/min/10^6 cells Moderate 0.70
hlm-clint Human liver microsomal intrinsic clearance 12.190 uL/min/mg protein Moderate 0.70
hppb Human plasma protein binding (% unbound) 17.750 % Moderate 0.70
kinase-safety-class ACVR2B,ALK,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,IRAK1,ITK,JAK1,KIT,MAP3K1,MAP3K21,MAP4K1,MAPK7,MARK4,NTRK2,PDK1,PDK2,PDK4,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK33,TTK,ULK1 36
kinase-selectivity-class ACVR2A,ACVR2B,AURKA,BRAF,CAMK2D,CDK9,CLK4,CSF1R,DDR1,DYRK1B,FLT3,GRK2,IRAK1,JAK1,MAP2K6,MAP3K1,MAP3K10,MAP3K21,MAP4K1,MAPK7,MARK4,NTRK1,PDK1,PRKDC,SIK2,SIK3,STK33,TTK,ULK1 29
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.990 Moderate 0.70
mh-clint Mouse hepatocyte intrinsic clearance 60.534 Moderate 0.70
mppb Mouse plasma protein binding (% unbound) 26.860 Moderate 0.70
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.020 Moderate 0.70
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 33.130 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 17.906 uL/min/10^6 cells Moderate 0.70
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.290 % Moderate 0.70
rppb Rat plasma protein binding (% unbound) 18.220 % Moderate 0.70
solubility-dd Solubility at pH 7.4 in DMSO 49.888 uM Moderate 0.70

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC P02CA04 ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
ANTHELMINTICS
ANTINEMATODAL AGENTS
Benzimidazole derivatives
CHEBI has role CHEBI:35443 anthelminthic drug

Related Drugs by ATC class:

P02CA Benzimidazole derivatives 6 drugs
albendazolefenbendazoleflubendazoleivermectinmebendazolethiabendazole

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.31 acidic
pKa2 13.2 acidic
pKa3 2.76 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D03623 KEGG_DRUG
C0055709 UMLSCUI
CHEBI:135067 CHEBI
CHEMBL1788401 ChEMBL_ID
DB13465 DRUGBANK_ID
C014415 MESH_SUPPLEMENTAL_RECORD_UI
35803 PUBCHEM_CID
3570 INN_ID
JF3KQ40J31 UNII

Pharmaceutical products:

None